Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

NCT03271255 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms

Interventions

DRUG: Apatinib Mesylate Tablets
DRUG: Bevacizumab Injection

Sponsor

Shenzhen People's Hospital